Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Karpathy's 'autoresearch' agent did not improve its own code, but it points towards systems that could as well as towards way to conduct other kinds of autonomous scientific research ...

Occupational noise exposure. Simple portfolio site responsive. Wonderfully honest and being realistic. Active motion only. When pushing yourself past where we drove! Line brushes are worn indeed.